Altre lingue AegirBio AB

Azioni

AEGIR

SE0014401121

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 17:29:50 03/05/2024			Variaz. 5gg	Var. 1 gen.
0,4805 ^SEK	-3,42%		-7,42%	-58,93%

09/04	AegirBio firma un accordo condizionale per un prestito di 45 milioni di corone svedesi con Atlas	MT
09/04	Il Presidente di AegirBio si dimette	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

AEGIRBIO AB ADVANCES FURTHER WITH "ACCESSIBILITY" MILESTONE COMPLETION IN RADx® TECH PROGRAM	30/04
AegirBio Unit Begins Arbitration Proceedings vs Salofa for Breach of Contract	19/04
AegirBio AB's subsidiary initiates arbitration against Salofa Oy	18/04
AegirBio Signs Conditional Agreement for SEK45 Million Loan With Atlas	09/04
AegirBio Chairman to Resign	09/04
AegirBio's chairman has announced his intention to leave the board of directors	09/04
AegirBio AB Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman	09/04
AegirBio enters into a conditional agreement on a MSEK 45 loan facility with Atlas Special Opportunities and an agreement to amend the outstanding convertible bonds, subject to EGM approval	09/04
AegirBio AB Enters into Conditional Agreement on a SEK 45 Million Loan Facility with Atlas Special Opportunities, LLC	09/04
AegirBio AB Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
AegirBio AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03
Aegirbio Expands Oral Health Scientific Advisory Board with Professor Iain L.C. Chapple	27/02
AegirBio AB Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board	27/02
Renowned Gastroenterologist, Dr. Adam S. Cheifetz, Joins AegirBio's Scientific Advisory Board	24/01
AegirBio AB Appoints Adam S. Cheifetz as Scientific Advisory Board	24/01
AegirBio AB: Atlas Special Opportunities, LLC calls for partial conversion of outstanding convertible bonds to a nominal amount of MSEK 5.00	20/12
AegirBio AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	24/11
AegirBio Receives Portion of National Institutes of Health Award	01/11
AegirBio Shifts Business Focus to Diagnostics Initiative in US	01/11
AegirBio AB Receives $239,547 award from the National Institutes of Health RADx Tech Program	01/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue AegirBio AB

Azioni

AEGIR

SE0014401121

Altre lingue

Filtri